NCT04287816

Brief Summary

Malnutrition of the fat-soluble nutrient vitamin E (α-tocopherol; αT) is problematic. Since αT is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate αT bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of αT) to validate eggs as a dietary tool to improve αT bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will dose- and time-dependently increase plasma bioavailability of spinach-derived deuterium-labeled αT without affecting time to maximal concentrations or half-lives. Further, phospholipid-rich egg yolk lipid will enhance nutrient bioavailability compared with vegetable oil. The outcome will therefore support an egg-based food pairing that can enhance the health benefits of plant-centric dietary patterns.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 22, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 27, 2020

Completed
1.3 years until next milestone

Study Start

First participant enrolled

June 1, 2021

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 15, 2024

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

December 2, 2025

Completed
Last Updated

December 2, 2025

Status Verified

November 1, 2025

Enrollment Period

3.1 years

First QC Date

February 22, 2020

Results QC Date

August 14, 2025

Last Update Submit

November 17, 2025

Conditions

Keywords

Vitamin EEggSpinach

Outcome Measures

Primary Outcomes (2)

  • Vitamin E Area Under the Curve (0-72 h)

    Area under the concentration-time curve of plasma deuterium-labeled alpha-tocopherol over 72 hours post ingestion.

    0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach

  • Vitamin E Cmax

    Maximum plasma concentration of deuterium-labeled alpha-tocopherol

    0-72 hours post-ingestion of spinach

Secondary Outcomes (4)

  • Vitamin E Tmax (hr)

    0-72 hours post-ingestion of spinach

  • Half-Life (hr)

    0-72 hours post-ingestion of spinach

  • Estimated Absorption (%Dose) of Vitamin E

    0-72 hours post-ingestion of spinach

  • Chylomicron Vitamin E

    0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach

Study Arms (8)

Zero hard-boiled egg at 0 h

EXPERIMENTAL

No eggs will be consumed on the test day. Deuterium-labeled spinach containing 5 mg αT will be ingested alone prior to the 72-h pharmacokinetics trial.

Other: Zero hard-boiled egg at 0 h

One hard-boiled egg at 0 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.

Other: One hard-boiled egg at 0 h

Two hard-boiled eggs at 0 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5mg αT will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.

Other: Two hard-boiled eggs at 0 h

Three hard-boiled eggs at 0 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.

Other: Three hard-boiled eggs at 0 h

One hard-boiled egg at 3 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.

Other: One hard-boiled egg at 3 h

One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.

Other: One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Two egg whites at 0 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested along with two egg whites prior to the 72-h pharmacokinetics trial.

Other: Two egg whites at 0 h

Vegetable oil at 0 h

EXPERIMENTAL

Deuterium-labeled spinach containing 5 mg αT will be ingested along with 9.6 grams of vegetable oil prior to the 72-h pharmacokinetics trial.

Other: Vegetable oil at 0 h

Interventions

No eggs will be consumed on test day along with spinach consumption

Zero hard-boiled egg at 0 h

One egg will be consumed on test day along with spinach consumption

One hard-boiled egg at 0 h

Two eggs will be consumed on test day along with spinach consumption

Two hard-boiled eggs at 0 h

Three eggs will be consumed on test day along with spinach consumption

Three hard-boiled eggs at 0 h

One egg will be consumed on test day three hours after spinach consumption

One hard-boiled egg at 3 h

Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption

One hard-boiled egg at 0 h + One hard-boiled egg at 3 h

Two egg whites will be consumed on test day along with spinach consumption

Two egg whites at 0 h

9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption

Vegetable oil at 0 h

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body Mass Index (BMI) = 19-25 kg/m2
  • Normolipidemic (total cholesterol \<240 mg/dL; triglyceride \<150 mg/dL)
  • Fasting glucose \<100 mg/dL
  • Normal hematocrit level (41%-50% for men and 36%-48% for women)
  • Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)
  • No use of dietary supplements for \>1 month
  • No use of medications that affect lipid or glucose metabolism
  • Non-smoker
  • No history of gastrointestinal disorders

You may not qualify if:

  • Egg allergy
  • Alcohol intake \> 2 drinks per day
  • Aerobic activity \>7 h/wk
  • Body mass change \>2 kg in the past 1 month
  • Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month
  • Vegetarian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ohio State University

Columbus, Ohio, 43210, United States

Location

Results Point of Contact

Title
Dr. Richard Bruno
Organization
Ohio State University

Study Officials

  • Richard S Bruno, Ph.D.

    Ohio State University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor and Principal Investigator

Study Record Dates

First Submitted

February 22, 2020

First Posted

February 27, 2020

Study Start

June 1, 2021

Primary Completion

July 15, 2024

Study Completion

July 15, 2024

Last Updated

December 2, 2025

Results First Posted

December 2, 2025

Record last verified: 2025-11

Locations